The intravenous iron drugs market is undergoing a significant transformation. With a projected rise from USD 3.27 billion in 2024 to USD 6.63 billion by 2032, growing at a CAGR of 9.31%, this market is capturing increasing attention across global healthcare systems. Iron deficiency anemia (IDA), often exacerbated by chronic conditions such as cancer, kidney disease, and gastrointestinal...
English
Arabic
Français
Español
Português
Deutsch
Türkçe
Dutch
Russian
Romaian
Portuguese (Brazil)
Greek